Diroximel Fumarate Patent Expiration

Diroximel Fumarate is Used for treating multiple sclerosis. It was first introduced by Biogen Inc in its drug Vumerity on Oct 29, 2019.


Diroximel Fumarate Patents

Given below is the list of patents protecting Diroximel Fumarate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Vumerity US10080733 Prodrugs of fumarates and their use in treating various diseases Sep 20, 2033 Biogen Inc
Vumerity US8669281 Prodrugs of fumarates and their use in treating various diseases Sep 20, 2033 Biogen Inc
Vumerity US9090558 Prodrugs of fumarates and their use in treating various diseases Sep 20, 2033 Biogen Inc


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Diroximel Fumarate's patents.

Given below is the list recent legal activities going on the following patents of Diroximel Fumarate.

Event Date Patent/Publication
Patent litigations
Resp. to req. for info. sent under 37 CFR 1.750 03 Jun, 2024 US8669281
Withdrawal of Application for PTE 01 May, 2024 US9090558
Withdrawal of Application for PTE 01 May, 2024 US10080733
Requirement for information sent under 37 CFR 1.750 04 Apr, 2024 US10080733
Requirement for information sent under 37 CFR 1.750 04 Apr, 2024 US9090558
Requirement for information sent under 37 CFR 1.750 04 Apr, 2024 US8669281
Notice of Final Determination -Election Required 29 Mar, 2024 US10080733
Notice of Final Determination -Election Required 29 Mar, 2024 US8669281
Notice of Final Determination -Election Required 29 Mar, 2024 US9090558
FDA Final Eligibility Letter 26 Apr, 2023 US10080733



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳